-
Views
-
Cite
Cite
Maria Leonarda M.L De Rosa, Piercarmine P. Cardace, Massimiliano M. Rossi, Alessandro A. de Cristofaro, Antonio A. Baiano, Carlo C. Vigorito, P-168: Long term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment, American Journal of Hypertension, Volume 14, Issue S1, April 2001, Page 86A, https://doi.org/10.1016/S0895-7061(01)01813-1
Close - Share Icon Share
Abstract
Objective: We evaluated the blood pressure lowering activity, tolerability and safety of Irbesartan (I) in 32 elderly hypertensive (sitting diastolic blood pressure, 90 to 115 mmHg) patients with chronic renal insufficiency including mild renal insufficiency (30 to 60 ml/min x 1.73 m2; n=30), moderate to severe renal insufficiency (10 to 29 ml/min x 1.73 m2; n=2) in one year trial.
Design and Methods: After a 3-week placebo period, once daily I was administered for 12 months at daily dose of 150 mg. A second, non-angiotensin-converting enzyme inhibitor, antihypertensive drug was added after 8 weeks as needed. Twenty-four-hour creatinine clearance was determined and renal clearance studies of inulin and paraminohippurate were done in a subset of 11 patients.
Results: Through sitting blood pressure were reduced at the end of the first week in all groups. At weeks 4, 8, 12 and after one year the reductions in systolic blood pressure/diastolic blood pressure averaged were -11.9/-8.7,-10.8/-9.4,and -14.7/-12.1mmHg in patients with mild renal insufficiency; -7.7/-6.3,-13.1/-11.8, and -14.1/-10.6 mmHg in moderate to severe renal insufficiency.Creatine clearance,glomerular filtration rate and effective renal plasma flow were stable.I was withdrawn in only 6 patients because of a clinical or laboratory adverse experience. Hyperkaliemia(>6mEq/L) requiring discontinuation of I occurred in only one(group 2)patient.
Conclusion: We conclude that once-daily I given as monotherapy at dose of 150 mg or in combination with other antihypertensive drugs,was effective in reducing blood pressure in elderly hypertensive patients with chronic renal disease and that I regimens were well tolerated in all groups.
- angiotensins
- antihypertensive agents
- irbesartan
- hypertension
- renal clearance function
- systolic blood pressure
- kidney failure, chronic
- blood pressure
- drug clearance
- kidney failure
- glomerular filtration rate
- inulin
- renal plasma flow, effective
- safety
- creatine
- enzyme inhibitors
- creatinine clearance
- renal impairment
- diastolic blood pressure
- older adult
- sitting position
